Melatoninergic receptor agonists and antagonists: Therapeutic perspectives;Agonistes et antagonistes des récepteurs mélatoninergiques: Perspectives thérapeutiques

Journal de la Societe de Biologie

Volumn 201, Issue 1, 2007, Pages 105-113

  Guardiola Lemaitre, Béatrice ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MELATONIN; MELATONIN RECEPTOR;

BODY TEMPERATURE; CIRCADIAN RHYTHM; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; MENTAL DISEASE; MOOD DISORDER; PATHOPHYSIOLOGY; PERIODICITY; PHYSIOLOGY; PINEAL BODY;

ANTIDEPRESSIVE AGENTS; BODY TEMPERATURE; CIRCADIAN RHYTHM; HUMANS; MELATONIN; MENTAL DISORDERS; MOOD DISORDERS; PERIODICITY; PINEAL GLAND; RECEPTORS, MELATONIN;

RODENTIA;

EID: 34548430145     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2007012     Document Type: Conference Paper

References (57)

1. Armstrong S. M. & Redman J. R., Melatonin and circadian rhythmicity. In Melatonin: biosynthesis, physiological effects and clinical applications, Yu H.S. & Reiter R.J. (eds.), 1993, CRC Press, Boca Raton, USA, pp. 187-224.
2. Armstrong S. M., McNulty O. M., Redman J. R., & Guardiola-Lemaitre B., Successful use of S20098 and melatonin in an animal model of delayed sleep phase syndrome (DSPS). Pharmacol. Biochem. Behav., 1993, 46, 45-49.
3. Bartness T. J., Demas G. E. & Song C. K., Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp. Biol. Med. (Maywood), 2002, 227, 36-76.
4. Benca R. M., Obermeyer W. H., Thisted R. A. & Gillin J. C., Sleep and psychiatric disorders. A meta-analysis. Arch. Gen. Psychiatry, 1992, 49, 651-668.
5. Bertaina-Anglade V., Mocaer E. & Drieu La Rochelle C., Antidepressant-like action of S20098 (agomelatine) in the learned helplessness test. J. Neuropsychopharmacol., 2002, 6, suppl. 1, S65.
6. Bourin M., Mocaer E. & Porsolt R., Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry neurosci., 2004, 29, 126-133.
7. Buijs R. M. & Kalsbeek A., Hypothalamic integration of central and peripheral clocks. Nature Reviews. Neuroscience, 2001, 2, 521-526.
8. Bylesjo E. I., Boman K. & Wetterberg L., Obesity treated with phototherapy: four case studies. Int. J. Eat Disord., 1996, 20, 443-446.
9. Dubocovich M. L., Cardinali D. P., Guardiola-Lemaitre B., Hagan R. M., Krause D. N., Sugden D. et al., Melatonin receptors 1998. In The IUPHAR Compendium of Receptor Characterization and Classification, Girdlestone D. (ed.), IUPHAR Media, London, pp. 188-193.
10. Ferrari E., Magri F., Pontiggia B., Rondanelli M., Fioravanti M., Solerte S. B. & Severgnini S., Circadian neuroendocrine functions in disorders of eating behavior. Eat Weight Disord., 1997, 2, 196-202.
11. Ferrari E., Fraschini F. & Brambilla F., Hormonal circadian rhythms in eating disorders. Biol. Psychiatry, 1990, 27, 1007-1020.
12. Flegal K. M., Graubard B. I., Williamson D. F. & Gail M. H., Excess deaths associated with underweight, overweight, and obesity. JAMA, 2005, 293, 1861-1867.
13. Guardiola-Lemaître B., Melatonin agonists/antagonist: from the receptor to the therapeutic application. Adv. In Pineal Research, 1994, 8. Morten Moller & Paul Pévet (eds). John Libbey & Company Ltd. pp. 333-348.
14. Guardiola-Lemaître B. J., Lenègre A. & Porsolt R., Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol. Biochem. Behav., 1992, 41, 405-408.
15. Guilleminault C., Efficacy of Agomelatine versus Venlafaxine on subjective sleep of patients with major depressive disorder. Eur. Neuropsychopharmacol., 2005, 15, S419.
16. Hedley A. A., Ogden C. L., Johnson C. L., Carroll M. D., Curtin L. R. & Flegal K. M., Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA, 2004, 291, 2847-2850.
17. Howell H. E., Guardiola B., Renard P. & Morgan P. J, Naphtalenic ligands reveal melatonin binding site heterogeneity. Endocrine, 1994, 2, 979-988.
18. Kennedy S. H. & Emsley R., Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 2006, 16, 93-100.
19. Kessler R. C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K. R., Rush A. J., Walters E. E. & Wang P. S., The epidemiology of major depressive disorder: results from the national Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, 3095-3105.
20. Klein D. C. & Weller J. L., Indole metabolism in the pineal gland: a circadian rhythm in N-acetyltransferase. Science, 1970, 169, 1093-1095.
21. Laitinen J. T., Viswanathan M., Vakkuri O. & Saavedra J. M., Differential regulation of the rat melatonin receptors: selective age-associated decline and lack of melatonin-induced changes. Endocrinology, 1992, 130, 2139-2144.
22. Launay J. M., Lemaitre B. J., Dreux C., Hartmann L. & Da Prada M., Melatonin synthesis by rabbit platelets. Life Sci.,1982, 31, 1487-1494.
23. Le Gouic S., Delagrange P., Atgie C., Nibbelink M., Hanoun N., Casteilla L., Renard P., Lesieur D. Guardiola-Lemaître B. & Ambid L., Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the Garden Dormouse. Int. J. Obes. Relat. Metab. Disord., 1996, 20, 661-667.
24. Lemaître B. J. & Hartmann J., Preparation of anti-melatonin antibodies and antigenic properties of the molecule. J. Immunol. Methods, 32, 339-347.
25. Lemaître B. J., Bouille J. & Hartmann J, Variations of urinary melatonin excretion in humans during the first 30 years of life. Clin. Chim. Acta, 1981, 110, 77-82.
26. Lerner A. B., Case J. D., Takahashi Y., Lee T. H. & Mori W., Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Amer. Chem. Soc., 1958, 80, 2587.
27. Lesieur D., Leclerc V., Chavatte P., Marot C., Renard P. & Guardiola-Lemaitre B., La mélatonine, prototype pertinent pour l'innovation thérapeutique. Thérapie, 1998, 53, 429-437.
28. Loo H., Hale A. & D'Haenen H., Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17, 239-247.
29. Martinet L., Guardiola-Lemaître B. & Mocaer E., Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependant. Pharmacol. Biochem. Behav., 1996, 54, 713-718.
30. Masson-Pévet M., Recio J., Guerrero H.Y., Mocaer E., Delagrange P., Guardiola-Lemaitre B. et al., Effects of two melatonin analogues, S20098 and S20928, on melatonin receptors in the pars tuberalis of the rat. J. Pineal Res., 1998, 25, 172-176.
31. Masson-Pévet M., Georges D., Kalsbeek A., Saboureau M., Lakhar-Ghazal N. & Pevet P., An attempt to correlate brain areas containing melatonin-binding sites with rhythmic functions: a study in five hibernator species. Cell Tissue Res., 1994, 278, 97-106.
32. McKeown R. E., Cuffe S. P. & Schulz R. M., US suicide rates by age group, 1970-2002: an examination of recent trends. Am. J. Public Health, 2006, 96, 1744-1751.
33. Millan M. J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., Rivet J. M. & Cussac D., The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther., 2003, 306, 954-964.
34. Mocaer E., Delalleau B., Bayer P. A. & de Bodinat C., Comment développer un antidépresseur au mécanisme d'action innovant : l'exemple de l'Agomélatine. Médecine/Sciences, 2005, 21, 888-893.
35. Mokdad A. H., Serdula M. K., Dietz W. H., Bowman B. A., Marks J. S. & Koplan J. P., the spread of the obesity epidemic in the United States, 1991-1998. JAMA, 1999, 282, 1519-1522.
36. Montgomery S. A., Kennedy S. H., Burrows G. D., Lejoyeux M. & Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol., 2004, 19, 271-280.
37. Morgan P. J., Barrett P., Howell E. & Helliwell R., Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int., 1994, 24, 101-146.
38. Nosjean O., Ferro M., Coge F., Beauverger M., Henlin J. M., Lefoulon F. et al., Identification of melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
39. Ostrowska Z., Buntner B., Zwirska-Korczala K., Marek B. & Nowak M., Circadian oscillation of melatonin, gonadotropins, sex hormones and SHBG in post-menopausal women showing android and gynoid type obesity. Endocr. Regul., 1996, 30, 133-134
40. Overstreet D. H., Pucilowski O., Rettori M. C., Delagrange P. & Guardiola-Lemaître B., Effects of melatonin receptor ligands on swim test immobility. Neuroreport, 1998, 26, 9, 249-253.
41. Papp M., Gruca P., Boyer P. A. & Mocaer E., Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacol. , 2003, 28, 694-703.
42. Perreau-Lenz S., Kalsbeek A., Garidou M. L., Wortel J., Van Der Vliet J., Van Heijningen C., Simonneaux V., Pévet P. & Buijs R. M., Suprachiasmatic control of melatonin synthesis in rats: inhibitory and stimulatory mechanisms. Eur. J. Neurosc., 2003, 17, 221-228.
43. Pitrosky B., Kirsch R., Malan A., Mocaer E. & Pevet P., Organisation of rat circadian rhythms during daily infusion of melatonin or S 20098, a melatonin agonist. Am. J. Physiol., 1999, 277, 812-828.
44. Pjrek E., Winkler D., Konstantinidis A., Willeit M., Praschak-Rieder N. & Kasper S., Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology, 2006, Dec. 15.
45. Prunet-Marcassus B., Desbazeille M., Bros A., Louche K., Delagrange P., Renard P., Casteilla L. & Penicaud L., Melatonin reduces body weight gain in Sprague-Dawley rats with diet-induced obesity. Endocrinology, 2003, 144, 5347-5352.
46. Rajaratnam S. M., Dijk D. J., Middleton B., Stone B. M. & Arendt J., Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J. Clin. Endocrinol. Metab., 2003, 88, 4303-4309.
47. Redman J. R. & Guardiola-Lemaitre B., The melatonin agonist, S20098: effects on the rat circadian system. Melatonin and the pineal gland - from basic science to clinical application. Elsevier Publisher 1993. Touitou Y., Arendt J. & Pevet P., editors. pp. 127-130.
48. Reppert S. M., Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J. Biol. Rhythms, 1997, 12, 528-531.
49. Rouillon F., Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol., 2006, 21 (suppl. 1), 31-35.
50. Souêtre E., Salvati E., Wehr T.A., Sack D.A, Krebs B. & Darcourt G., Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. Am. J. Psychiatry, 1988, 145, 1133-1137.
51. Thase M. E., Treatment issues related to sleep and depression. J. Clin. Psychiatry, 2000, 61, 48-50.
52. Touitou Y., Bogdan A., Auzéby A. & Selmaoui B., Mélatonine et vieillissement. Thérapie, 1998, 53, 473-478.
53. Weil Z. M ., Hotchkiss A. K., Gatien M. L., Pieke-Dahl S. & Nelson R. J., Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res. Bull., 2006, 15, 68, 425-429.
54. Wirz-Justice A., Circadian disturbances in depression: therapeutic perspectives. Medicographia, 2003, 25, 29-36.
55. Ying S. W., Rusak B., Delagrange P., Mocaer E., Renard P. & Guardiola-lemaître B., Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur. J. Pharmacol., 1996, 296, 33-42.
56. Yous S., Lesieur D., Andrieux J., Howell T., Morgan P., Guardiola-Lemaitre B., Novel naphtalenic ligands with high affi-nity for the melatonin receptor. Am. J. Med. Chem., 1992, 35, 1484-1486.
57. Agomélatine. Drugs of the Future, 2003, 28, 7-13.